The 68th World Health Assembly opens in Geneva
19 May 2015 | By Victoria White
Angela Merkel addressed delegates on the first morning of the Health Assembly, calling for a new plan to deal with “catastrophes” like the Ebola outbreak...
List view / Grid view
News
Regeneron and Sanofi announce positive Phase 2b dupilumab data in asthma
19 May 2015 | By Victoria White
Regeneron and Sanofi have shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate to-severe asthma, who are uncontrolled despite treatment with inhaled corticosteroids and long-acting beta agonists (ICS/LABA).
Experts share real-world experience with biosimilar infliximab in patients with inflammatory bowel disease
19 May 2015 | By Victoria White
Clinical experience of biosimilar infliximab shows that the treatment is comparable to the reference medicinal product in terms of efficacy and safety...
CPhI Worldwide announces members of its 2015 Expert Panel
18 May 2015 | By Victoria White
CPhI Worldwide has announced its Expert Panel for CPhI Worldwide 2015 ahead of the eagerly anticipated annual report (3rd edition)...
First patient dosed in Phase 2 study of tipifarnib in advanced cancers with HRAS mutations
18 May 2015 | By Victoria White
The first patient has been dosed in the Phase 2 clinical trial of tipifarnib in patients with locally advanced tumours that carry HRAS mutations...
FDA Fast Track designation granted to luspatercept for the treatment of patients with beta-thalassemia
18 May 2015 | By Victoria White
The FDA has granted Fast Track designations to luspatercept for two separate indications for the treatment of patients with beta-thalassemia...
Endo to acquire Par Pharmaceutical in a transaction valued at $8.05 billion
18 May 2015 | By
Endo is set to acquire privately-held Par Pharmaceutical in a transaction valued at $8.05 billion. The acquisition will expand Endo's generics business...
Data from two Phase 3 studies of cystic fibrosis investigational medicine Orkambi published
18 May 2015 | By Victoria White
Data from two Phase 3 studies of Orkambi, an investigational medicine designed to treat the underlying cause of cystic fibrosis, have been published...
Boehringer Ingelheim acquires Pharmaxis’ investigational drug PXS4728A
18 May 2015 | By Victoria White
Boehringer Ingelheim has acquired Pharmaxis’ investigational drug PXS4728A, to develop it for the treatment of NASH and to prevent its consequences...
Amgen presents positive first Phase 2 data for AMG 334 in the prevention of episodic migraine
18 May 2015 | By Victoria White
Amgen has announced the first results from its global Phase 2 study evaluating the efficacy and safety of AMG 334 for the prevention of episodic migraine...
Abbvie receives Orphan Drug Designation for Humira for the investigational treatment of hidradenitis suppurativa
The US Food and Drug Administration (FDA) has granted Abbvie’s Humira® (adalimumab) Orphan Drug Designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease.
SAGE achieves 77% response rate in Phase 1/2 clinical trial of SAGE-547 in super-refractory status epilepticus
15 May 2015 | By Victoria White
SAGE-547 demonstrated robust activity, with a 77% response rate in patients with SRSE, in a successfully completed Phase 1/2 clinical trial...
AcelRx awarded contract from the US Department of Defence to develop ARX-04
15 May 2015 | By Victoria White
AcelRx Pharmaceuticals has entered into a contract to develop ARX-04 worth up to $17.0 million, supported by the US Department of Defence (DoD)...
Takeda discontinues alisertib Phase 3 trial in relapsed or refractory peripheral T-cell lymphoma
15 May 2015 | By Victoria White
Takeda has decided to discontinue the Phase 3 trial of alisertib (MLN8237) for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)...
Teva presents further data from Phase IIb trial of TEV-48125 in chronic migraine at IHC 2015
14 May 2015 | By Victoria White
Teva will present further data from its chronic migraine Phase IIb study of TEV-48125 at the 17th Congress of the International Headache Society on Friday...
